ExcepGen develops a platform that modifies cellular responses to DNA and mRNA, enhancing the efficacy of nucleic acid therapeutics. This approach mitigates undesirable cellular pathways, improving the delivery and effectiveness of gene therapies and vaccines for rare diseases.
Funding
$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AP+1Founders
Product
Problem
Nucleic acid therapeutics, such as gene therapies and mRNA vaccines, face challenges related to undesirable cellular responses that can limit their efficacy. Current approaches primarily focus on modifying the chemistry and delivery of nucleic acids, overlooking the cell's inherent reaction to these molecules.
Solution
ExcepGen is developing a platform that modulates cellular responses to DNA and mRNA, enhancing the effectiveness of nucleic acid therapeutics. By dampening specific undesirable cellular pathways, ExcepGen aims to improve the delivery and overall impact of gene therapies and vaccines. This approach seeks to unlock the full potential of nucleic acid medicines by addressing the cell's dynamic biological response. The platform is being applied to preventative and therapeutic vaccines, rare diseases, and gene therapy applications.
Target Audience
The primary target audience includes researchers and pharmaceutical companies developing gene therapies and mRNA vaccines, particularly those focused on rare diseases.
Features
- Modulation of cellular pathways to enhance nucleic acid therapeutic efficacy
- Dampening of undesirable cellular responses to DNA and mRNA
- Application to gene therapies, preventative vaccines and therapeutic vaccines
- Platform designed to improve the delivery and impact of nucleic acid medicines